Limited Activity of Miltefosine in Murine Models of Cryptococcal Meningoencephalitis and Disseminated Cryptococcosis
Open Access
- 1 February 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (2) , 745-750
Abstract
Miltefosine is an alkyl phosphocholine with good oral bioavailability and in vitro activity against Cryptococcus species that has gained interest as an additional agent for cryptococcal infections. Our objective was to further evaluate the in vivo efficacy of miltefosine in experimental in vivo models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Mice were infected intracranially or intravenously with either C. neoformans USC1597 or H99. Miltefosine treatment (1.8 to 45 mg/kg of body weight orally once daily) began at either 1 h or 1 day postinoculation. Fluconazole (10 mg/kg orally twice daily) or amphotericin B deoxycholate (3 mg/kg intraperitoneally once daily) served as positive controls. In our standard models, miltefosine did not result in significant improvements in survival or reductions in fungal burden against either C. neoformans isolate. There was a trend toward improved survival with miltefosine at 7.2 mg/kg against disseminated cryptococcosis with the H99 strain but only at a low infecting inoculum. In contrast, both fluconazole and amphotericin B significantly improved survival in mice with cryptococcal meningoencephalitis and disseminated cryptococcosis due to USC1597. Amphotericin B also improved survival against both cryptococcal infections caused by H99. Combination therapy with miltefosine demonstrated neither synergy nor antagonism in both models. These results demonstrate limited efficacy of miltefosine and suggest caution with the potential use of this agent for the treatment of C. neoformans infections.Keywords
This publication has 28 references indexed in Scilit:
- A murine model of Cryptococcus gattii meningoencephalitisJournal of Antimicrobial Chemotherapy, 2012
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Effect of Therapeutic Chemical Agents In Vitro and on Experimental Meningoencephalitis Due toNaegleria fowleriAntimicrobial Agents and Chemotherapy, 2008
- Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis PatientsAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Activities of Miltefosine and Two Novel Antifungal Biscationic Salts against a Panel of 77 DermatophytesAntimicrobial Agents and Chemotherapy, 2007
- Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D StudyPLOS Medicine, 2007
- Treatment of Bolivian Mucosal Leishmaniasis with MiltefosineClinical Infectious Diseases, 2007
- Development of miltefosine as an oral treatment for leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999